Fig. 6: A2-APM treatment promotes DC maturation and results in pro-inflammatory transformation of macrophages and decreased myeloid-derived suppressor cells. | Nature Communications

Fig. 6: A2-APM treatment promotes DC maturation and results in pro-inflammatory transformation of macrophages and decreased myeloid-derived suppressor cells.

From: Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy

Fig. 6

a Representative histograms display each marker’s (MHCII, CD80 and CD86) expression levels compared to isotype controls. b MFI of each marker’s expression were calculated based on (a), n = 3 mice. c Quantification of tumor-infiltrating CD86+ F4/80+ and CD206+ F4/80+ cells three days after two treatments with saline, free aPD-L1, free PTX, A2-AM, A2-PM, APM and A2-APM. Saline treated mice (n = 3), free aPD-L1, free PTX, A2-AM, A2-PM, APM and A2-APM treated mice (n = 4). d Quantification of tumor-infiltrating Gr-1+ CD11b+, Ly6C+ and Ly6G+ cells three days after two treatments with saline, free aPD-L1, free PTX, A2-AM, A2-PM, APM and A2-APM. Saline treated mice (n = 3), free aPD-L1, free PTX, A2-AM, A2-PM, APM and A2-APM treated mice (n = 4). All statistics are expressed as mean ± SD. Statistical significance was calculated by one-way ANOVA with Fisher’s LSD test. Source data are provided as a Source Data file.

Back to article page